Apply to NIAID’s notice of funding opportunity (NOFO) Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01, Clinical Trial Not Allowed) for funding to conduct research on radiation biodosimetry assays and devices. The NOFO supports radiation research at all stages of development for identifying biomarkers of injury and developing assays or devices for the purpose of triage, including assessing absorbed dose or predicting health outcomes of acute or delayed injuries resulting from radiation exposure during a public health emergency.
Scientific Objective
This initiative’s end goal is to generate data towards obtaining approval or clearance from the FDA to use in a radiological or nuclear public health emergency.
NIAID is interested in supporting studies that propose the following example research areas:
- Evaluating and characterizing radiation-induced biomarkers for the purpose of triage and definitive dose assessment, or identification of those that are predictive of early and delayed injuries, based on markers that could include, but are not limited to, gene or protein expression; DNA or protein modifications; metabolomic, lipidomic, immunomodulatory, cytogenetic, inflammatory, biochemical, and/or physico-chemical changes.
- Analyzing signature biokinetics (i.e., biomarkers that persist over a range of time, permitting use in a radiation public health emergency – such as 30 minutes to days, weeks, or months post-exposure).
- Investigating influence of confounders on the kinetics of the technique/biomarker (e.g., sex, age, smoking, health status, comorbidities, and current medications), type of radiation, partial-body irradiation, other combined injuries (e.g., burn, trauma, wound), or use of approved hematopoietic acute radiation syndrome therapeutics.
- Developing imaging techniques to identify and characterize radiation injury to organs/tissues of physiological systems.
You must include milestones in your application; NIAID will consider applications not including milestones to be nonresponsive and not review them. Plan detailed, quantitative research milestones and timelines for your project, and, if selected for funding, NIAID staff will use them to better assess your annual progress.
The NOFO also identifies studies that are nonresponsive, e.g., characterization and development of biomarkers of carcinogenesis, projects not specifically addressing radiation injury biomarkers, projects that are focused on medical countermeasures to mitigate or treat radiation-induced injuries, and applications proposing HIV/AIDS studies. If you propose a nonresponsive study, we will not review your application. Refer to the NOFO for the complete list.
Award and Budget Details
Application budgets are not expected to exceed $350,000 in annual direct costs and must reflect the actual needs of the project.
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Deadline
This NOFO has a single due date. Submit your application by May 31, 2024, at 5 p.m. local time of the applicant organization.
Have Questions?
Direct inquiries to Dr. Merriline M. Vedamony, NIAID’s scientific/research contact, at Merriline.Satyamitra@nih.gov or 240-669-5432. For concerns specific to peer review, instead contact Dr. Michael Opata at michael.opata@nih.gov or 240-627-3319.